DNA repair disease
MONDO:0021190A disease that has its basis in the disruption of DNA repair.
Also known as: DNA repair disorder, deficiency of DNA repair, disorder of DNA repair, DNA Repairs, deficient, DNA repair deficiency, DNA repair deficiency disorders, DNA repair, deficient, DNA repair-deficiencies
105 clinical trials for this condition and its sub-types, 13 tagged with DNA repair disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of DNA repair disease
-
Fanconi anemia 29 trials · 42 incl. sub-types
22 sub-types
- Fanconi anemia complementation group D1 6 trials
- Fanconi anemia complementation group A 4 trials
- Fanconi anemia complementation group E 4 trials
- Fanconi anemia complementation group N 2 trials
- Fanconi anemia, complementation group S 2 trials
- Fanconi anemia complementation group B 0 trials
- Fanconi anemia complementation group C 0 trials
- Fanconi anemia complementation group D2 0 trials
- Fanconi anemia complementation group F 0 trials
- Fanconi anemia complementation group G 0 trials
- Fanconi anemia complementation group I 0 trials
- Fanconi anemia complementation group J 0 trials
- Fanconi anemia complementation group L 0 trials
- Fanconi anemia complementation group O 0 trials
- Fanconi anemia complementation group P 0 trials
- Fanconi anemia complementation group Q 0 trials
- Fanconi anemia complementation group R 0 trials
- Fanconi anemia complementation group T 0 trials
- Fanconi anemia complementation group U 0 trials
- Fanconi anemia complementation group V 0 trials
- Fanconi anemia, complementation group W 0 trials
- Fanconi anemia, complementation group 10 0 trials
-
Mismatch repair cancer syndrome 5 trials · 36 incl. sub-types
4 sub-types
- Mismatch repair cancer syndrome 1 34 trials
- Mismatch repair cancer syndrome 2 0 trials
- Mismatch repair cancer syndrome 3 0 trials
- Mismatch repair cancer syndrome 4 0 trials
-
Cockayne syndrome 6 trials
4 sub-types
- Cockayne spectrum with or without cerebrooculofacioskeletal syndrome 0 trials
- Cockayne syndrome type 1 0 trials
- Cockayne syndrome type 2 0 trials
- Cockayne syndrome type 3 0 trials
-
Xeroderma pigmentosum 4 trials · 6 incl. sub-types
10 sub-types
- Xeroderma pigmentosum group F 1 trial
- Xeroderma pigmentosum variant type 1 trial
- Xeroderma pigmentosum group A 0 trials
- Xeroderma pigmentosum group B 0 trials
- Xeroderma pigmentosum group C 0 trials
- Xeroderma pigmentosum group D 0 trials
- Xeroderma pigmentosum group E 0 trials
- Xeroderma pigmentosum group G 0 trials
- Xeroderma pigmentosum, autosomal dominant, mild 0 trials
- Xeroderma pigmentosum, complementation group J 0 trials
-
Karyomegalic interstitial nephritis 2 trials
-
Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 0 trials · 2 incl. sub-types
-
COFS syndrome 1 trial
5 sub-types
- Cerebrooculofacioskeletal syndrome 1 0 trials
- Cerebrooculofacioskeletal syndrome 2 0 trials
- Cerebrooculofacioskeletal syndrome 3 0 trials
- Cerebrooculofacioskeletal syndrome 4 0 trials
- Xeroderma pigmentosum group G 0 trials
-
Nijmegen breakage syndrome 1 trial
-
UV-sensitive syndrome 0 trials
3 sub-types
- UV-sensitive syndrome 1 0 trials
- UV-sensitive syndrome 2 0 trials
- UV-sensitive syndrome 3 0 trials
-
Photosensitive trichothiodystrophy 0 trials
3 sub-types
- Trichothiodystrophy 1, photosensitive 0 trials
- Trichothiodystrophy 2, photosensitive 0 trials
- Trichothiodystrophy 3, photosensitive 0 trials
-
New surgical trick may improve nose shape after cleft lip repair
Disease control CompletedThis study tested a surgical technique called a dermal roll flap to support the nostril base in 45 people who had a previous cleft lip repair. The flap uses extra skin from the lip to lift and stabilize the nostril on the cleft side. Researchers measured changes in nostril positi…
Sponsor: King Edward Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested two drugs, cabozantinib and pamiparib, together in 44 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and understand side effects. The drugs work by blocking certain enzymes t…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Experimental combo aims to supercharge cancer immunotherapy
Disease control CompletedThis early-phase trial tested the safety of combining two drugs—L-NMMA and pembrolizumab (Keytruda)—in 12 adults with various advanced cancers. Pembrolizumab helps the immune system recognize cancer cells, while L-NMMA may remove a chemical barrier that blocks immune attack. The …
Phase 1 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC